Mdb Capital Holdings, Llc · NASDAQ:MDBH
Mdb Capital — Q2 2026 Earnings Presentation
20 slides from Mdb Capital's earnings presentation, Aug 13, 2026
Slide 1: We Launch Category-Defining Companies
NASDAQ: MDBH Second Quarter and First Half 2026 Update | August 13, 2026 We Launch Category-Defining Companies From promise to monetization — focus, discipline, and distributing the value we create to our shareholders
Slide 2: Forward-Looking Statements & Disclosures
Forward-Looking Statements & Disclosures This presentation contains "forward-looking statements." These forward-looking statements are made as of the date they were first issued and were based on current expectations, estimates, forecasts and projections as well as the beliefs and assumptions of man
Slide 3: Today's Agenda
Today's Agenda The backdrop explains both our results and our strategy shift — so we start there 1 The Backdrop: A Market of Extremes 2 What It Means for MDB — An Assessment 3 Our Plan: Maximizing the Value of the Core Four 4 The Core Four: Public Ventures · PatentVest · eXoZymes · Paulex Bio 5 Fina
Slide 4: The Backdrop: A Market of Extremes
The Backdrop: A Market of Extremes Capital has crowded into the biggest public companies and the biggest private AI deals ~50% 43% $510B 70%+ of S&P 500 market value now sits of ALL global venture funding in record global venture funding in of Q2 2026 startup capital went in just the top 20 companie
Slide 5: The Sub-$200M Market Has Been Evacuated
The Sub-$200M Market Has Been Evacuated The smallest public companies have been left out of the recovery Micro-cap IPOs (Nasdaq/NYSE) 90 • ~1,000 companies, roughly 2% of total U.S. market capitalization 80 — with little or no research coverage 80 70 • Institutional mandates exclude the tier: most f
Slide 6: What This Means for MDB — An Assessment
MDB What This Means for MDB — An Assessment We are not happy with where we are — and we are keeping it in perspective THE HARD TRUTHS THE PERSPECTIVE • It is often darkest before the dawn — and in this • Our performance post-IPO is not what we hoped tier, dawn arrives suddenly — we own that • Value
Slide 7: Our Response: From Promise to Monetization
Our Response: From Promise to Monetization What we said at year end — and where we are focusing now YEAR END — THE PROMISE NOW — THE MONETIZATION • AI transforms our sourcing, diligence, • Monetize the Core Four: Public Ventures, and launch model PatentVest, eXoZymes, Paulex Bio • Scale from 1 launc
Slide 8: The Core Four
The Core Four Four platforms, each with a defined path to value realization PUBLIC VENTURES PATENTVEST Self-clearing broker-dealer & clearing platform AI-native IP law platform — first ABS IP law firm Years of investment complete — now launching as the backdrop AI is disrupting patent law; we believ
Slide 9: Public Ventures — Self-Clearing as a Growth Moat
Public Ventures — Self-Clearing as a Growth Moat The investment phase is complete — now we launch it off on its own WHY IT MATTERS WHAT WE BUILT THE LAUNCH • Self-clearing lets a firm grow its • CMA started 2019 → DTC • Position Public Ventures as the lines of business without the approval May 2023
Slide 10: PatentVest — The Right Platform at the Right Time
PatentVest — The Right Platform at the Right Time AI is disrupting the legal industry — and patent law is first in line $750M $10–15B $30B+ valuation of Manifest — an AI-native ABS annual US IP prosecution spend — a far AI legal tech market immigration-law firm funded in April larger space than immi
Slide 11: eXoZymes (NASDAQ: EXOZ)
eXoZymes (NASDAQ: EXOZ) Cell-free biomanufacturing — entering the commercialization phase, at scale The Transition Underway • eXoZymes is transitioning into its commercialization phase — a threshold synthetic biology has never crossed • Its process can be outsourced to contract manufacturers and ~4.
Slide 12: Paulex Bio — Disrupting Diabetes Care
Paulex Bio — Disrupting Diabetes Care Beta-cell regeneration — potentially the most impactful drug we have ever launched The Science & Strategy MAJOR MILESTONES • A pill that stimulates production of insulin-producing beta cells — a potential Type 1 and Type 2 diabetes breakthrough Q4 2025 • Over 80
Slide 13: The Core Four — Positions & Paths
The Core Four — Positions & Paths Real assets, real ownership — value realization is the work of the back half and beyond Asset MDB Position Stage Path to Value Realization eXoZymes (EXOZ) ~4.1M shares + warrants Public (Nasdaq) Market discovery of cell-free biomanufacturing Paulex Bio ~7.1M shares
Slide 14: Risk Factors & Acknowledgments
Risk Factors & Acknowledgments A plan, a team, and a clear view of the road ahead Microcap Market Conditions Monetization Timing The sub-$200M market remains evacuated; liquidity and Strategic partnerships, spin-outs, and IPOs depend on distribution constraints are real and ongoing counterparties an
Slide 15: Protect Against Dilution. Distribute the Value.
OUR PLAN Protect Against Dilution. Distribute the Value. MONETIZE DON'T DILUTE DISTRIBUTE Realize value from the Core Four We do not intend to fund the As platform value is realized, our — platforms built with years of future by issuing MDBH equity intent is to see it flow to MDBH shareholder OpEx i
Slide 16: First Half 2026 — Operations
First Half 2026 — Operations Two transactions completed; two more expected in the back half 2 2 4 banking transactions additional transactions core platforms moving completed in H1 2026 expected in H2 2026 toward monetization • We had hoped to complete more than two transactions in the first half —
Slide 17: Capital Discipline — A Leaner Platform
Capital Discipline — A Leaner Platform Fixed overhead covered by fees; equity upside kept for shareholders Annual Fixed Overhead ($M) 12 • Target: ~$1.5M per quarter in total fixed overhead — roughly $10M 10 $6M per year — as Public Ventures and PatentVest launch off on their own 8 $6M • Expected tr
Slide 18: Launching Big Ideas — A $5–6M-a-Year Exercise
Launching Big Ideas — A $5–6M-a-Year Exercise A small, covered fixed cost with historically enormous leverage Run the launch platform at $5–6M per year — fixed overhead 1 Operate lean covered by transaction fees Keep sourcing and launching game-changing companies — 2 Launch big ideas 29 years, 18 IP
Slide 19: Our Perspective in Summary
Our Perspective in Summary Microcap value recognition is an event, not a trend • We have seen this movie before: companies we backed looked all but dead — then the core underlying value was recognized, and billion-dollar valuations emerged • In the sub-$200M tier, re-rating happens suddenly — a data
Slide 20: Knowing that we can make a positive difference
NASDAQ: MDBH Knowing that we can make a positive difference is what drives us every day. Thank you for being part of our community at MDB driving to make a difference.. Questions? Our shareholders' success is our success. MDB Capital Holdings · August 2026 · © All Rights Reserved